Plasma aldosterone levels and development of insulin resistance: Prospective study in a general population

Hypertension

Volumn 58, Issue 6, 2011, Pages 1043-1048

  Kumagai, Eita ^a   Adachi, Hisashi ^a,b   Jacobs, David R ^c   Hirai, Yuji ^a   Enomoto, Mika ^a   Fukami, Ako ^a   Otsuka, Maki ^a   Kumagae, Shun Ichi ^a   Nanjo, Yasuki ^a   Yoshikawa, Kuniko ^a   Esaki, Eishi ^a   Yokoi, Kanako ^a   Ogata, Kinuka ^a   Kasahara, Akiko ^a   Tsukagawa, Eri ^a   Ohbu Murayama, Kyoko ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aldosterone; Epidemiology; Insulin; Population

Indexed keywords

ALDOSTERONE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ALDOSTERONE; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INSULIN RESISTANCE; JAPAN; MALE; MIDDLE AGED; POSTURE; POTASSIUM; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 83155180252     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.180521     Document Type: Article

References (34)

1. Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006;1:1039-1045.
2. Giacchetti G, Sechi LA, Rilli S, Carey RM. The rennin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126.
3. Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension. 1992;19: II26-II29.
4. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep. 2003;5:106-109.
5. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776-783.
6. Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka Toshiyasu. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology. 2009;150:1662-1669.
7. Kraus D, Jager J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005;37:455-459.
8. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-γ, and proinflammatory adipokines. Circulation. 2008;117:2253-2261.
9. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F, and the Primary Aldosteronism Prevalence in Hypertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008;93:2566-2571.
10. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007;30:2349-2354.
11. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab. 2010;95:1986-1990.
12. Catena C, Colussi G, Di Fabio A, Marzano L, Uzzau A, Sechi LA. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm metab Res. 2010;42:440-445.
13. Widimsky J Jr, Strauch B, Sindelka G, Skrha J. Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol Res. 2001;50:603-607.
14. Strauch B, Widimsky J Jr, Sindelka G, Skrha J. Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res. 2003;52:503-506.
15. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91:3457-3463.
16. Adachi H, Hirai Y, Sasaki S, Enomoto M, Fukami A, Kumagai E, Esaki E, Imaizumi T. Trends in dietary intakes and serum cholesterol levels over 50 years in Tanushimaru in Japanese men. Food Nutr Sci. 2011;2:476-481.
17. Koga Y, Hashimoto R, Adachi H, Tsuruta M, Tashiro T, Toshima H. Recent Trends in Cardiovascular Disease and Risk Factors in the Seven Countries Study. Lessons for Science From the Seven Countries Study. A 35-Year Collaborative Experience in Cardiovascular Disease Epidemiology. Springer-Verlag: Tokyo, Japan; 1994:63-74.
18. Hino A, Adachi H, Toyomasu K, Yoshida N, Enomoto M, Hiratsuka A, Hirai Y, Satoh A, Imaizumi T. Very long chain N-3 fatty acids intake and carotid atherosclerosis: an epidemiological study evaluated by ultrasonography. Atherosclerosis. 2004;176:145-149.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
20. Ura N, Saitoh S, Shimamoto K. Clinical diagnosis of metabolic syndrome 1: metabolic syndrome and insulin resistance. Intern Med. 2007;46:1283-1284.
21. Ohnishi H, Saitoh S, Ura S, Takagi F, Obara H, Akasaka H, Oimatsu H, Shimamoto K. Relationship between insulin resistance and accumulation of coronary risk factors. Diabetes Obes Metab. 2002;4:388-393.
22. Ohnishi H, Saitoh S, Takagi S, Ohata J, Takeuchi H, Isobe N, Katoh N, Chiba Y, Fujiwara T, Akasaka H, Shimamoto K. Incidence of insulin resistance in obese subjects in a rural Japanese population: the Tanno and Sobetsu Study. Diabetes Obes Metab. 2005;7:83-87.
23. Akasaka H, Katsuya T, Saitoh S, Sugimoto K, FU Y, Takagi S, Ohnishi H, Rakugi H, Ura N, Shimanoto K, Ogihara T. Effects of angiotensin II type 1 receptor gene polymorphisms on insulin resistance in a Japanese general population: the Tanno-Sobetsu Study. Hypertens Res. 2006;26:961-967.
24. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, on behalf of the collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
25. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, Kotchen TA. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704-711.
26. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: Is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension. 2008;51:1252-1258.
27. Kidambi S, Kotchen JM, Krishnaswami S, Grim CE, Kotchen TA. Hypertension, insulin resistance, and aldosterone: sex-specific relationships. J Clin Hypertens. 2009;11:130-137.
28. Vasan RS, Evans JC, Larson MG, Larson MG, Wilson PWF, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
29. Ingelsson E, Pencina MJ, Tofler GH, Benjamin E, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D'Agostino Sr RB, Wang TJ, Vasan RS. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984-992.
30. Sperling MA. AT. P-sensitive potassium channels: neonatal diabetes mellitus and beyond. N Engl J Med. 2006;355:507-510.
31. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes. 2002;51:1226-1232.
32. Ohishi M, Takeya Y, Tatara Y, Yamamoto K, Onishi M, Maekawa Y, Kamide K, Rakugi H. Strong suppression of the rennin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study. Hypertens Res. 2010;33:1150-1154.
33. Haller H, Ito S, Izzo J Jr. Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; for the ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907-917.
34. Andraws R, Brown DL. Effect of inhibition of the rennin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Med. 2007;99:1006-1012.